Concepedia

1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study

Kensei Yamaguchi, Y-J. Bang, Satoru Iwasa, Naotoshi Sugimoto, M.H. Ryu, Daisuke Sakai, Hyun Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, J. Lee,

Annals of Oncology · 2020 · 44 citations · 1 references

DOIFull text

Open access

Concepts

References

1

1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study

Kensei Yamaguchi, Y-J. Bang, Satoru Iwasa et al. · Annals of Oncology · 2020 · 44 citations · Full text

, , +17